英將用“基因剪刀”技術(shù)發(fā)展新藥 <img src="/data/attachement/jpg/site1/20150202/a41f726749f6163957c20a.jpg" border="0" />
中國日報網(wǎng) 2015-02-02 13:49
British pharmaceutical giant AstraZeneca has announced a research programme to develop a new generation of medicines to treat the genetic causes of many debilitating diseases, such as diabetes, heart disease and many cancers.
英國制藥巨頭阿斯利康制藥日前宣布一項研究計劃,開發(fā)新一代藥物,治療許多因遺傳因素引起的使人衰弱的疾病,例如糖尿病、心臟病和不少癌癥。
AstraZeneca said it plans to make use of so-called CRISPR genome-editing technology for key therapeutic areas including oncology. The technology enables researchers to “edit” the genes of certain cells relatively quickly and accurately.
阿斯利康稱,其計劃是在包括腫瘤學(xué)的重要治療領(lǐng)域利用被稱作CRISPR的“基因剪刀”技術(shù)?!盎蚣舻丁奔夹g(shù)使得研究人員可以相對快而準(zhǔn)地“編輯”一些細(xì)胞的基因。
例句:
Some companies are using gene-editing techniques to change the plant's existing DNA rather than insert foreign genes.
一些公司正使用“基因剪刀”技術(shù)來改變植物現(xiàn)在的DNA,而不是插入外來基因。
(中國日報網(wǎng)英語點(diǎn)津 Bernard)